Page last updated: 2024-09-05

lenalidomide and Diffuse Large B-Cell Lymphoma

lenalidomide has been researched along with Diffuse Large B-Cell Lymphoma in 131 studies

Research

Studies (131)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (3.05)	29.6817
2010's	64 (48.85)	24.3611
2020's	63 (48.09)	2.80

Authors

Authors	Studies
Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE	1
Ghosh, N; Hu, B; Jacobs, R; Levine, J; Moore, DC; Moyo, TK; Park, SI; Smith, ET; Soni, AC	1
Ambarkhane, S; Augustin, M; Duell, J; Endell, J; Geiger, S; Liu, H; Obr, A; Rosenwald, A; Silverman, IM	1
Bartlett, NL; Becker-Hapak, M; Berrien-Elliott, MM; Cashen, AF; Desai, S; Fehniger, TA; Fischer, A; Foster, M; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Luo, J; Maddocks, K; Mosior, M; Schmidt, A; Skidmore, ZL; Wagner-Johnston, ND; Ward, JP; Watkins, MP	1
Abraham, I; Calamia, M; McBride, A	1
Dong, T; Jing, F; Song, W; Wang, L; Wang, Y; Xiao, S; Xue, H	1
Boxhammer, R; Cho, SY; Endell, J; Heitmueller, C; Her, JH; Hoeres, T; Hwang, YK; Patra-Kneuer, M; Pretscher, D; Schanzer, J; Steidl, S; Wilhelm, M	1
Westin, J	1
Ambarkhane, S; Cordoba, R; Kapetanakis, V; Prawitz, T; Sabatelli, L; Sharma, A; Westley, T	1
Ansell, SM; Cerhan, JR; Desai, SH; Feldman, A; Habermann, TM; Inwards, DJ; Johnston, P; King, RL; LaPlant, B; Macon, WR; Maurer, M; Micallef, I; Mwangi, R; Nowakowski, GS; Pederson, L; Porrata, LF; Wang, Y; Witzig, TE; Young, JR	1
Chiu, H; Chopra, VS; Colombo, M; Estevez, MO; Gandhi, AK; Hagner, PR; Loos, R; Patel, N; Towfic, F; Waldman, MF	1
Eagers, KA; Janes, A; Moore, DC; Pineda-Roman, M	1
Ambarkhane, S; Fleury, I; Greil, R; Hess, G; Huang, D; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Salles, G; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL	1
Álvaro-Naranjo, T; Carnicero-González, F; Casanova-Espinosa, M; de la Cruz-Merino, L; de la Cruz-Vicente, F; Espejo-García, P; Fernández-Álvarez, R; Fernández-Román, I; Gálvez-Carvajal, L; García-Domínguez, DJ; Gómez-Codina, J; Guirado-Risueño, M; Gumà-Padrò, J; Hontecillas-Prieto, L; Jiménez-Cortegana, C; Labrador, J; Martín García-Sancho, A; Martínez-Banaclocha, N; Marylene, L; Navarro, M; Nogales-Fernández, E; Palazón-Carrión, N; Provencio-Pulla, M; Ríos-Herranz, E; Rodríguez-Abreu, D; Rodríguez-García, G; Rueda-Domínguez, A; Salar-Silvestre, A; Sánchez-Beato, M; Sánchez-Margalet, V	1
Caccese, E; Messori, A	1
Cherng, HJ; Westin, JR	1
Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U	1
Ahmed, S; Davis, RE; Fanale, M; Fayad, L; Feng, L; Flowers, CR; Fowler, N; Green, MR; Griffith, D; Hagemeister, F; Iyer, SP; Lee, HJ; Lu, Y; Ma, MCJ; McDonnell, T; Nair, R; Nastoupil, L; Neelapu, S; Oki, Y; Pinnix, C; Rodriguez, A; Samaniego, F; Scott, DW; Steiner, R; Sun, R; Tewari, S; Vega, F; Wang, M; Westin, J	1
Cheng, S; Fang, H; Huang, HY; Jiang, L; Li, JF; Ouyang, BS; Qian, Y; Shi, ZY; Wang, L; Xu, PP; Yi, HM; Zhao, WL; Zhu, Y	1
Yamaguchi, M	1
Chen, L; Guo, X; Liang, T; Liu, J; Mi, R; Yin, Q	1
Alarcon Tomas, A; Alperovich, A; Anagnostou, T; Avigdor, A; Batlevi, CL; Besser, MJ; Dahi, PB; Danylesko, I; Devlin, SM; Fein, JA; Fingrut, WB; Flynn, JR; Fraint, E; Fried, S; Giralt, S; Imber, BS; Jacoby, E; Kedmi, M; Lin, RJ; Nagler, A; Palomba, ML; Perales, MA; Roshal, M; Salles, GA; Sauter, C; Scordo, M; Shah, GL; Shah, N; Shem-Tov, N; Shimoni, A; Shouval, R; Yahalom, J; Yerushalmi, R	1
Alig, SK; Alizadeh, AA; Cherng, HJ; Craig, AFM; Davis, RE; Fayad, L; Feng, L; Flowers, CR; Green, MR; Hagemeister, F; Kurtz, DM; Lee, HJ; Macaulay, CW; McDonnell, TJ; Nastoupil, LJ; Neelapu, SS; Oki, Y; Rodriguez, MA; Turturro, F; Vega, F; Westin, JR	1
Maddocks, K; Nedved, A; Nowakowski, GS	1
Beldi-Ferchiou, A; Briere, J; Casasnovas, RO; Claudel, A; Corront, B; De Colella, JS; Delfau-Larue, MH; Fruchart, C; Gaulard, P; Ghesquieres, H; Godard, N; Haioun, C; Jais, JP; Lazarovici, J; Morschhauser, F; Nicolas-Virelizier, E; Oberic, L; Perrot, A; Salles, G; Thieblemont, C; Tilly, H; Zamali, I	1
Ding, K; Jiang, X; Wang, X; Yu, L	1
Armitage, JO; Bierman, PJ; Bociek, RG; Caimi, PF; Ganguly, S; Lunning, M; Lyden, L; Meza, JL; Vose, JM	1
Aurran-Schleinitz, T; Belmecheri, N; Bladé, JS; Bouabdallah, R; Coso, D; Lopez Almeida, L; Mescam, L; Montes de Oca, C; Noel, R; Schiano de Colella, JM; Slama, B; Vey, N; Zemmour, C	1
Cordoba, R; Fleury, I; Greil, R; Hess, G; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Sabatelli, L; Salles, G; Sporchia, A; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL	1
Bilgin, YM; Boersma, R; Bossuyt, PM; Chamuleau, MED; de Jong, D; de Jonge, AV; de Jongh, E; Dinmohamed, AG; Kersten, MJ; Koene, H; Mous, R; Nijland, M; Rutten, EGGM; Sandberg, Y; van Werkhoven, E; Veldhuis, MS; Vermaat, JSP; Zwinderman, AH	1
Jin, Z; Li, D; Li, J; Li, X; Liu, H; Liu, Z; Qing, K; Wang, L; Wang, Y; Xiang, R; Xu, Z; Xue, K; Zhang, Y; Zhu, H	1
André, M; Belada, D; Bergua Burgues, JM; Burke, JM; Dirnberger-Hertweck, M; Duell, J; Kopeckova, K; Mukhopadhyay, A; Nowakowski, GS; Persona, EP; Pichler, P; Staber, PB; Stevens, D; Trneny, M; Wagner, S; Waldron-Lynch, M	1
Annibali, O; Arcari, A; Ballerini, F; Bellei, M; Celli, M; Cesaretti, M; Fabbri, A; Gini, G; Lanza, F; Liberati, AM; Luminari, S; Mannina, D; Marcheselli, L; Marino, D; Merli, F; Musuraca, G; Olivieri, A; Pascarella, A; Pavone, V; Petrini, M; Plenteda, C; Pozzi, S; Tani, M; Tisi, MC; Tucci, A; Zilioli, VR	1
Baile, M; Bergua, J; Caballero, D; Campo, E; Dlouhy, I; Enjuanes, A; Espeso, M; González-Barca, E; Grande, C; Jarque, I; López-Guillermo, A; Martín García-Sancho, A; Montes-Moreno, S; Redondo, A; Rodríguez, G; Salar, A; Sancho, JM	1
Bu, X; Li, C; Wang, L; Zhang, X; Zhao, P; Zhu, D	1
Chen, J; Liu, L; Qi, T; Song, W; Sun, J; Tang, Y; Wang, Z; Xu, S; Yang, J; Zhang, R	1
Li, D; Shang, Y; Zhao, H	1
Abdulla, FR; Di Raimondo, C; Querfeld, C; Rosen, ST; Zain, J	1
Abraham, J; Bouabdallah, R; Bron, D; Caballero, D; Casadebaig, ML; Casasnovas, RO; Catalano, J; Cohen, AM; Coiffier, B; Costello, R; da Silva, MG; Daguindau, N; Deeren, D; Eisenmann, JC; Fitoussi, O; Fruchart, C; Gaulard, P; Gonzalez, H; Greil, R; Grosicki, S; Howlett, S; Le Du, K; Lionne-Huyghe, P; Morschhauser, F; Mounier, N; Nicolas-Virezelier, E; Obéric, L; Perrot, A; Pica, GM; Roulin, L; Snauwaert, S; Takeshita, K; Thieblemont, C; Tilly, H; Tricot, S; Trotman, J; van Eygen, K	1
Baran, A; Barr, PM; Burack, R; Casulo, C; Evans, A; Friedberg, JW; Reagan, PM; Rodgers, TD; Williams, AM; Zent, C	1
Abraham, J; Bouabdallah, R; Briere, J; Casasnovas, O; Chartier, L; Choufi, B; Corront, B; Cottereau, AS; Feugier, P; Fitoussi, O; Fruchart, C; Gaulard, P; Godmer, P; Gonzalez, H; López-Guillermo, A; Meignan, M; Morschhauser, F; Oberic, L; Pica, GM; Ribrag, V; Roulin, L; Salles, G; Sanhes, L; Sebban, C; Simon, M; Snauwaert, S; Thieblemont, C; Tilly, H; Trotman, J; Vercellino, L	1
Ansell, SM; Asmann, Y; Cerhan, JR; Feldman, AL; Gandhi, AK; Habermann, TM; Hartert, KT; King, RL; Krull, JE; Larson, MC; Link, BK; Macon, WR; Manske, M; Maurer, MJ; Novak, AJ; Nowakowski, GS; Sarangi, V; Slager, S; Wenzl, K; Witzig, TE; Yang, ZZ	1
Angelillo, P; Arcari, A; Bertoldero, G; Calimeri, T; Cecchetti, C; Ciceri, F; De Lorenzo, D; Di Rocco, A; Fabbri, A; Ferreri, AJM; Foppoli, M; Frezzato, M; Nonis, A; Perrone, S; Ponzoni, M; Re, A; Rusconi, C; Sassone, M; Scarano, E; Spina, M; Steffanoni, S; Stelitano, C; Tarantino, V; Volpetti, S; Zaja, F; Zambello, R	1
Argnani, L; Broccoli, A; Casadei, B; Cavo, M; Gentilini, M; Zinzani, PL	1
Ambarkhane, S; André, M; Dirnberger-Hertweck, M; Dreyling, M; Duell, J; Fingerle-Rowson, G; Gaidano, G; González Barca, E; Jurczak, W; Kalakonda, N; Liberati, AM; Maddocks, K; Nagy, Z; Obr, A; Salles, G; Tournilhac, O; Weirather, J	1
Bojan, A; Dima, D; Iluta, S; Jitaru, C; Pasca, S; Petrushev, B; Piciu, D; Roman, A; Rus, I; Teodorescu, P; Tomuleasa, C; Zdrenghea, M	1
Hoy, SM	1
Lue, JK; O'Connor, OA	1
Hu, S; Wang, W; Zhang, W; Zhang, Y; Zhou, D; Zou, D	1
Harris, LJ; Martin, M; Patel, K	1
Di, M; Huntington, SF; Olszewski, AJ	1
Arens, AIJ; Bakunina, K; Beeker, A; Bilgin, YM; Boersma, RS; Bohmer, LH; Burggraaff, CN; Chamuleau, MED; de Jong, D; de Jongh, E; Diepstra, A; Dierickx, D; Durian, MF; Hijmering, N; Hoekstra, O; Huijbregts, J; Kersten, MJ; Koene, HR; Lugtenburg, PJ; Mandigers, C; Marijt, EAF; Mous, R; Nijland, M; Schouten, HC; Snijders, TJF; Tick, LW; van den Berg, A; van Imhoff, GW; van Rees, B; Vermaat, JSP; Visser, O; Zijlstra, JM	1
Abraham, J; Bijou, F; Bonnet, C; Casasnovas, RO; Damaj, G; Dartigues-Cuillères, P; Fabiani, B; Farhat, H; Feugier, P; Gat, E; Haioun, C; Jardin, F; Le Calloch, R; Maisonneuve, H; Malak, S; Oberic, L; Paget, J; Peyrade, F; Pica, GM; Puyade, M; Ruminy, P; Salles, G; Thieblemont, C; Tilly, H; Waultier-Rascalou, A	1
Amengual, JE; Casulo, C; Cohen, JB; Friedberg, JW; Habermann, TM; Hong, F; Kahl, BS; Khan, N; King, RL; Kostakoglu, L; Leonard, JP; Little, RF; Macon, WR; Nagargoje, GG; Nowakowski, GS; Reynolds, CM; Richards, KL; Scott, DW; Wade, JL; Wagner-Johnston, N; Witzig, TE	1
Belada, D; Bergua, JM; Cavallo, F; Chiappella, A; Czuczman, M; Gascoyne, RD; Hersey, S; Hong, X; Hudak, K; Izutsu, K; Jin, J; Jurczak, W; Kato, K; Kilcoyne, A; Mócikova, H; Molinari, AL; Nowakowski, GS; Özcan, M; Piazza, F; Russo, J; Scott, DW; Tani, M; Vitolo, U; Wade, S; Witzig, TE; Yamamoto, K; Yoon, DH; Zhang, J; Zhang, Q; Zhu, J	1
Cheson, BD; Nowakowski, G; Salles, G	1
Beaupre, D; Chhabra, S; de Vos, S; Huang, DW; Kimball, AS; Kwei, K; Neuenburg, JK; Phillips, T; Ping, J; Popplewell, L; Staudt, LM; Wilson, WH; Wright, G	1
Cooper, DL; Goldfinger, M	1
Bertram, S; Dührsen, U; Ganser, A; Hüttmann, A; Ibach, S; Kroschinsky, F; Tometten, M	1
Ai, L; Guo, T; Hu, Y; Jiang, H; Li, C; Lin, Z; Liu, L; Mei, H; Qian, Q; Sun, Y; Tang, L; Wang, J; Wu, J; Wu, Y; Xia, L	1
Bakhtiari, M; Boyle, M; Chavez, EA; Chong, LC; He, HH; He, MY; Isaev, K; Joynt, J; Kridel, R; Lackraj, T; Privé, GG; Scott, DW; Silva, A; Steidl, C; Tiedemann, RE; Tong, KI; Xu, MC; Yoon, S	1
Abrisqueta, P; Ambarkhane, S; André, M; Augustin, M; De Vos, S; Dirnberger-Hertweck, M; Dreyling, M; Duell, J; Gaidano, G; González-Barca, E; Jurczak, W; Kalakonda, N; Liberati, AM; Maddocks, KJ; Menne, T; Nagy, Z; Obr, A; Rosenwald, A; Salles, G; Tournilhac, O; Weirather, J	1
Bernard, S; Casasnovas, RO; Copie-Bergman, C; Feugier, P; García-Sancho, AM; Ghesquieres, H; Gomes da Silva, M; Greil, R; Griolet, S; Grosicki, S; Haioun, C; Morschhauser, F; Renaud, L; Thieblemont, C; Trotman, J; van Eygen, K	1
Ambarkhane, S; Barbui, AM; Castellino, C; Dey, D; Feinberg, B; Fingerle-Rowson, G; Fowler, NH; Frezzato, M; Kurukulasuriya, NC; Marino, D; Meli, E; Nowakowski, GS; Parche, S; Rodgers, T; Salles, G; Tillmanns, S; Winderlich, M; Zinzani, PL	1
Carrasco, V; Cases, E; Gómez Gonzalez, C; Lázaro Sierra, J	1
Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A	1
Witzig, TE	1
Altenbuchinger, M; Bertoni, F; Cascione, L; Chiappella, A; Ciccone, G; Inghirami, G; Kohler, C; Kwee, I; Rinaldi, A; Vitolo, U	1
Chen, Y; Fang, Y; Fei, XC; Janin, A; Jiang, XF; Leboeuf, C; Li, B; Song, Q; Sun, YF; Wang, CF; Wang, L; Xu, PP; Yan, ZX; Zhao, WL; Zhao, Y	1
Batista, CR; DeKoter, RP; Solomon, LA	1
Cameron, H; Drennan, AC; Kellicut, A; Kelm, A; Kimpara, S; Li, Y; Lu, L; Rui, L; Rumball, I; Selzer, C; Waldmann, TA; Wang, F; Zhang, M; Zhu, F	1
Bagot, M; Barete, S; Beylot-Barry, M; Bonnet, N; Bouabdallah, R; Dalle, S; Duval-Modeste, AB; Frison, E; Grange, F; Gros, A; Ingen-Housz-Oro, S; Joly, P; Maillard, A; Maubec, E; Merlio, JP; Mermin, D; Mortier, L; Pham-Ledard, A; Quereux, G; Ram-Wolff, C; Templier, I; Vergier, B; Vially, PJ	1
Huang, H; Liu, Y; Shi, W; Sun, C; Wang, X; Zhang, Y	1
He, W; Min, X; Yang, X	1
Ayed, AO; Cavallo, F; Chiappella, A; Congiu, AG; Gaidano, G; Laplant, BR; Macon, WR; Musuraca, G; Nowakowski, GS; Pederson, L; Re, A; Spina, M; Vitolo, U; Witzig, T	1
Till, BG	1
Anwer, F; Durer, C; Durer, S; Faridi, W; Fraz, MA; Ijaz, A; Khan, AY; Kumar, A; Malik, SU; Nasar, A; Qureshi, A; Tariq, MJ; Usman, M	1
Ma, LY; Su, L	1
Ansell, SM; Castellino, A; Cavallo, F; Chiappella, A; Ciccone, G; Congiu, A; Foran, JM; Gaidano, G; Habermann, TM; Inghirami, G; King, RL; LaPlant, BR; Macon, WR; Molinari, AL; Nowakowski, GS; Pavone, V; Pederson, LD; Reeder, CB; Rivera, CE; Spina, M; Tucci, A; Vitolo, U; Witzig, TE	1
Batchelor, TT; Grommes, C; Nayak, L; Tun, HW	1
Evens, AM; Konry, T; Mckenney, S; Ravi, D; Sabhachandani, P; Sarkar, S	1
Beauchesne, P; Cassoux, N; Chevrier, M; Chinot, O; Choquet, S; Ghesquieres, H; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Laadhari, M; Le Garff-Tavernier, M; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Savignoni, A; Schmitt, A; Soumelis, V; Soussain, C; Touitou, V; Turbiez, I	1
Chukavina, MM; Gabeeva, NG; Koroleva, DA; Kovrigina, AM; Obukhova, TN; Zvonkov, EE	1
Bishop, MR; Cohen, KS; Godfrey, JK; Karmali, R; Karrison, T; Kline, JP; Nabhan, C; Rapoport, AP; Smith, SM; Stadler, WM; Venugopal, P	1
Bertino, JR; Cooper, DL; Goldfinger, M; Xu, M	1
Argnani, L; Balzarotti, M; Broccoli, A; Casadei, B; Cascavilla, N; Castellino, C; Chiappella, A; Conconi, A; Cox, MC; Devizzi, L; Fama, A; Gaudio, F; Goldaniga, MC; Marasca, R; Marino, D; Monaco, F; Musuraca, G; Paolini, R; Patti, C; Rigacci, L; Romano, A; Tani, M; Tecchio, C; Visco, C; Zancanella, M; Zinzani, PL	1
Madabhavi, IV; Modi, MG; Revannasiddaiah, S; Sarkar, MS	1
Beaupre, DM; Dang, NH; Delioukina, M; Ghosh, N; Goy, A; Kingsley, E; Knapp, M; Morgan, DS; Munoz, J; Neuenburg, JK; Ping, J; Ramchandren, R; Ruan, J	1
Badillo, M; Bejarano, M; Champlin, R; Chen, Y; Cheng, N; Desai, M; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hosing, C; Kwak, L; Neelapu, SS; Newberry, KJ; Oki, Y; Pro, B; Romaguera, J; Shah, J; Thomas, S; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zhang, L	1
Argnani, L; Derenzini, E; Pellegrini, C; Pileri, S; Zinzani, PL	1
Foschi, FG; Lanzi, A; Marano, G; Savini, P; Stefanini, GF	1
Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M	1
Desai, M; Newberry, KJ; Ou, Z; Romaguera, J; Wang, M; Zhang, L	1
Cai, Q; Champlin, RE; Desai, M; Fu, K; Huang, H; Jiang, W; Liang, R; Qian, Z; Wang, M; Westin, J; Zhang, L	1
Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Chetaille, B; Coso, D; Esterni, B; Ivanov, V; Olive, D; Schiano, JM; Stoppa, AM	1
Beaven, AW; Bejot, C; Bhattacharyya, P; Carini, C; Chow, KF; Donato, ML; Feldman, T; Gadaleta, G; Goy, A; Kdiry, S; Mato, AR; Pecora, AL; Protomastro, EA; Rowley, SD; Smith, J; Stives, S; Timberg, M; Valentinetti, M; Yang, X; Yannotti, KM	1
Flohr, A; Schuelper, N; Trümper, L; Wulf, GG	1
Baldi, I; Botto, B; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; Congiu, A; Dreyling, M; Fattori, PP; Franceschetti, S; Gaidano, G; Gaudiano, M; Inghirami, G; Ladetto, M; Liberati, AM; Molinari, AL; Pavone, V; Rossi, G; Salvi, F; Spina, M; Vitolo, U; Zaccaria, A; Zanni, M; Zinzani, P	1
Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE	1
Gałązka, K; Gruchała, A; Jurczak, W; Krawczyk, K; Skotnicki, AB	1
Yamamoto, K	1
Jain, MK; Menke, DM; Sher, T; Swaika, A	1
Dahlman, KB; Hames, ML; Iams, WT; Reddy, NM; Richards, KL; Talbott, MS; Tsai, JP	1
Fowler, NH	1
Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE	1
Amantangelo, MD; Barnes, L; Bjorklund, C; Breider, M; Cai, T; Chiu, H; Chopra, R; Couto, S; Daniel, TO; Fontanillo, C; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Khambatta, G; Klippel, A; Kosek, J; Lopez-Girona, A; Lu, G; Man, HW; Narla, RK; Pourdehnad, M; Raymon, H; Rychak, E; Schafer, PH; Thakurta, A; Trotter, M; Waldman, M; Wang, M	1
Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A	1
Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E	1
Jin, Z; Li, J; Li, X; Liu, Z; Ouyang, Y; Qing, K; Wang, W; Xu, Z	1
Chiappella, A; Flament, J; Gascoyne, RD; Nowakowski, GS; Repici, J; Spina, M; Vitolo, U; Witzig, TE; Zhang, L	1
Argnani, L; Broccoli, A; Pellegrini, C; Zinzani, PL	1
Bettelli, S; Luminari, S; Maiorana, A; Salati, M; Tarantino, V	1
Cuzzocrea, S; Ferrero, S; Ghione, P; Marabese, A; Mian, M; Mondello, P; Pitini, V; Steiner, N; Willenbacher, W	1
Bouabdallah, R; Coso, D; Garciaz, S; Schiano de Colella, JM	1
Chan, TS; Khong, PL; Kwong, YL	1
Chen, H; Greer, JP; Morgan, DS; Park, SI; Reddy, NM; Richards, KL	1
Arcari, A; Bertoldero, G; Calimeri, T; Cecchetti, C; Chiozzotto, M; Couto, S; Fabbri, A; Ferreri, AJ; Frezzato, M; Govi, S; Nonis, A; Ponzoni, M; Re, A; Ren, Y; Rocco, AD; Rusconi, C; Sassone, M; Scarfò, L; Spina, M; Stelitano, C; Zaja, F; Zambello, R	1
Cole, CE; Ervin-Haynes, A; Habermann, TM; Justice, G; Lam, W; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB	1
Fricker, J	1
Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Chetaille, B; Chuto, G; Coso, D; Fezoui, H; Ivanov, V; Rey, J; Schiano, JM; Stoppa, AM; Tabouret, E	1
Amadori, D; Asioli, S; Cangini, D; Ceccolini, M; Fattori, PP; Giannini, MB; Matteucci, F; Musuraca, G; Ronconi, S	1
Bouabdallah, R; Buckstein, R; Czuczman, MS; Ervin-Haynes, AL; Guo, P; Haioun, C; Pietronigro, D; Polikoff, JA; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zinzani, PL	1
Czuczman, MS; Deeb, G; Goy, A; Hernandez-Ilizaliturri, FJ; Macon, WR; Malik, F; Pileri, SA; Witzig, TE; Zinzani, PL	1
Rubenstein, JL; Stewart, PJ; Treseler, PA	1
Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE	1
Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Zinzani, PL	1
Habermann, TM	1
Balasubramanian, S; Buggy, JJ; Ceribelli, M; Emre, NC; Ferrer, M; Guha, R; Kohlhammer, H; Mathews, LA; Platig, J; Powell, J; Shaffer, AL; Shinn, P; Staudt, LM; Thomas, C; Waldmann, TA; Wright, G; Xiao, W; Xu, W; Yang, Y; Young, RM; Zhang, M; Zhao, H	1
Chopra, R; Heise, C; Kosek, J; Schafer, PH; Wang, M; Zhang, LH	1
Habermann, T; Menon, S; Witzig, T	1

Reviews

22 review(s) available for lenalidomide and Diffuse Large B-Cell Lymphoma

Article	Year
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison. Advances in therapy, 2022, Volume: 39, Issue:6 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab; Treatment Outcome	2022
Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer treatment reviews, 2022, Volume: 110 Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine	2022
[Current status and future prospects of diffuse large B-cell lymphoma treatment]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9 Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Receptors, Chimeric Antigen; Rituximab; Vincristine	2022
Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials. Clinical and experimental medicine, 2023, Volume: 23, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Febrile Neutropenia; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Randomized Controlled Trials as Topic	2023
Tafasitamab: First Approval. Drugs, 2020, Volume: 80, Issue:16 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Approval; Drug Resistance, Neoplasm; European Union; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; United States; United States Food and Drug Administration	2020
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. The Lancet. Haematology, 2020, Volume: 7, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Genetic Heterogeneity; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Precision Medicine; Prednisone; Prognosis; Rituximab; Vincristine	2020
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International journal of molecular sciences, 2020, Nov-13, Volume: 21, Issue:22 Topics: Adoptive Transfer; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Triazoles	2020
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. The oncologist, 2021, Volume: 26, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Rituximab	2021
Diffuse large B-cell lymphoma: new targets and novel therapies. Blood cancer journal, 2021, 04-05, Volume: 11, Issue:4 Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Development; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Rituximab	2021
Lenalidomide in DLBCL: are we past the cell of origin? Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Treatment Outcome; Vincristine	2021
Two cases of permanent indwelling catheter for long-term administration of intrapleural chemotherapy. Archivos de bronconeumologia, 2017, Volume: 53, Issue:10 Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Catheters, Indwelling; Dexamethasone; Drainage; Fatal Outcome; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Pleural Effusion, Malignant; Rituximab; Thalidomide; Thoracentesis	2017
Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review. Cancer biology & therapy, 2018, 07-03, Volume: 19, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; CD5 Antigens; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Treatment Outcome	2018
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Current treatment options in oncology, 2018, 07-21, Volume: 19, Issue:9 Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult	2018
Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. Current treatment options in oncology, 2018, 09-01, Volume: 19, Issue:10 Topics: Adenine; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Female; Frail Elderly; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine	2018
Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape	2019
Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature. Terapevticheskii arkhiv, 2018, Aug-17, Volume: 90, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Germinal Center; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Progression-Free Survival; Vincristine	2018
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. Journal of hematology & oncology, 2013, Aug-02, Volume: 6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunomodulation; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Thalidomide; Tumor Microenvironment	2013
Accelerated therapeutic progress in diffuse large B cell lymphoma. Annals of hematology, 2014, Volume: 93, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Randomized Controlled Trials as Topic; Rituximab; Thalidomide	2014
[Standard of care and new drugs for diffuse large B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine	2014
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine	2015
Lenalidomide for the treatment of B-cell lymphoma. Expert opinion on investigational drugs, 2016, Volume: 25, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Thalidomide	2016
New developments in the management of diffuse large B-cell lymphoma. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Vincristine; Vindesine	2012

Trials

47 trial(s) available for lenalidomide and Diffuse Large B-Cell Lymphoma

Article	Year
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood cancer journal, 2021, 09-25, Volume: 11, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Treatment Outcome; Vincristine; Young Adult	2021
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022, 03-31, Volume: 139, Issue:13 Topics: Brentuximab Vedotin; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Treatment Outcome	2022
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-01, Volume: 28, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome	2022
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study. The lancet. Healthy longevity, 2022, Volume: 3, Issue:7 Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Frail Elderly; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Piperidines; Rituximab	2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood advances, 2023, 04-11, Volume: 7, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Vincristine	2023
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. British journal of haematology, 2023, Volume: 201, Issue:2 Topics: Aged; Cell Count; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prognosis; Rituximab	2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study. British journal of haematology, 2023, Volume: 202, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Transplantation, Autologous; Treatment Outcome	2023
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma. Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prospective Studies; Rituximab; Treatment Outcome	2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood, 2023, Oct-19, Volume: 142, Issue:16 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Vincristine	2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study. Blood, 2023, 10-26, Volume: 142, Issue:17 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Frail Elderly; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab; Treatment Outcome	2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO. British journal of haematology, 2023, Volume: 203, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neutropenia; Rituximab; Thrombocytopenia	2023
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. British journal of haematology, 2020, Volume: 189, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Quality of Life; Rituximab; Vincristine	2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood, 2020, 04-16, Volume: 135, Issue:16 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prognosis; Rituximab; Tumor Burden; Vincristine	2020
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, Volume: 35, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Vincristine; Young Adult	2021
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. Hematological oncology, 2020, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate	2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet. Oncology, 2020, Volume: 21, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult	2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica, 2020, 12-01, Volume: 105, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; Vincristine	2020
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 04-20, Volume: 39, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Vincristine; Young Adult	2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 04-20, Volume: 39, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Vincristine; Young Adult	2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. Leukemia & lymphoma, 2021, Volume: 62, Issue:9 Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Treatment Outcome; Vincristine	2021
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. Blood cancer journal, 2021, 05-17, Volume: 11, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lenalidomide; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Survival Analysis	2021
Frontiers in immunology, 2021, Volume: 12 Topics: Humans; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Remission Induction	2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica, 2021, 09-01, Volume: 106, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Transplantation, Autologous; Treatment Outcome	2021
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Aug-01, Volume: 35, Issue:22 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Placebos; Prednisone; Rituximab; Survival Rate; Thalidomide; Vincristine	2017
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. British journal of haematology, 2018, Volume: 182, Issue:3 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Lineage; Cyclophosphamide; Doxorubicin; Gene Expression Profiling; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Treatment Outcome; Vincristine	2018
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. The Journal of investigative dermatology, 2018, Volume: 138, Issue:9 Topics: Aged; Aged, 80 and over; Biopsy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; France; Humans; Immunologic Factors; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Remission Induction; Skin; Skin Neoplasms; Survival Rate; Treatment Outcome	2018
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood cancer journal, 2018, 06-26, Volume: 8, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Rituximab; Treatment Outcome; Vincristine	2018
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Intention to Treat Analysis; Intraocular Lymphoma; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Proof of Concept Study; Prospective Studies; Remission Induction; Rituximab	2019
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer, 2019, 06-01, Volume: 125, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Translocation, Genetic; Treatment Outcome; Vincristine	2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood, 2019, 09-26, Volume: 134, Issue:13 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome	2019
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia, 2013, Volume: 27, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Rituximab; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2013
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Middle Aged; Remission Induction; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica, 2013, Volume: 98, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Doxorubicin; Female; Humans; Italy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine	2013
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. British journal of haematology, 2014, Volume: 166, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome	2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Vincristine	2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-20, Volume: 33, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Phenotype; Prednisone; Prognosis; Rituximab; Thalidomide; Treatment Outcome; Vincristine	2015
Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism. Experimental hematology, 2015, Volume: 43, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hypothyroidism; Immunologic Factors; Interferon-gamma; Interleukin-12; Interleukin-15; Interleukin-6; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha	2015
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood, 2015, Aug-06, Volume: 126, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays	2015
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult	2016
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future oncology (London, England), 2016, Volume: 12, Issue:13 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Thalidomide; Vincristine	2016
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica, 2016, Volume: 101, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab; Salvage Therapy; Thalidomide	2016
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Leukemia, 2017, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Risk Assessment; Rituximab; Survival Rate; Thalidomide; Young Adult	2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. The Lancet. Haematology, 2017, Volume: 4, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quality of Life; Thalidomide; Treatment Outcome	2017
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide	2008
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; International Agencies; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Thalidomide; Treatment Outcome; Young Adult	2011
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia, 2011, Volume: 25, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Rituximab; Survival Rate; Thalidomide; Treatment Outcome; Vincristine	2011
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Rituximab; Thalidomide	2011

Other Studies

62 other study(ies) available for lenalidomide and Diffuse Large B-Cell Lymphoma

Article	Year
Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. British journal of haematology, 2022, Volume: 196, Issue:4 Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Rituximab	2022
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leukemia & lymphoma, 2022, Volume: 63, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse	2022
Economic evaluation of polatuzumab-bendamustine-rituximab Journal of medical economics, 2021, Volume: 24, Issue:sup1 Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab	2021
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China. Hematological oncology, 2022, Volume: 40, Issue:4 Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail Elderly; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Retrospective Studies; Rituximab	2022
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Surface; Cell- and Tissue-Based Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab	2022
Always be prepared for success. Blood, 2022, 03-31, Volume: 139, Issue:13 Topics: Brentuximab Vedotin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	2022
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood cancer journal, 2022, 05-03, Volume: 12, Issue:5 Topics: Disease-Free Survival; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Positron-Emission Tomography; Prospective Studies	2022
Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 08-02, Volume: 28, Issue:15 Topics: Histone Deacetylase Inhibitors; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Ubiquitin-Protein Ligases	2022
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Treatment Outcome	2023
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-15, Volume: 28, Issue:18 Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Oxaliplatin; Retrospective Studies; Rituximab; Treatment Outcome	2022
Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:13 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	2022
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-15, Volume: 28, Issue:18 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies; Treatment Outcome	2022
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 02-01, Volume: 41, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Piperidines; Rituximab	2023
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia, 2023, Volume: 37, Issue:1 Topics: Adult; Aged; Antigens, CD19; Humans; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Receptors, Chimeric Antigen; Remission Induction	2023
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The oncologist, 2023, 03-17, Volume: 28, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local	2023
Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. Cancer medicine, 2023, Volume: 12, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Neutropenia; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Tumor Microenvironment; Vincristine	2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large Annals of hematology, 2023, Volume: 102, Issue:7 Topics: Adolescent; Adult; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab	2023
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients. Blood cancer journal, 2023, 05-22, Volume: 13, Issue:1 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Rituximab; Treatment Outcome; Vincristine	2023
Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma. Cellular oncology (Dordrecht), 2023, Volume: 46, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD19; Cell- and Tissue-Based Therapy; Humans; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Receptors, Chimeric Antigen; Tumor Microenvironment	2023
Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report. Annals of hematology, 2023, Volume: 102, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab	2023
Zanubrutinib, lenalidomide, and rituximab (ZR2 regimen) for HIV-associated diffuse large B-cell lymphoma: a real-world analysis from China. AIDS (London, England), 2023, 10-01, Volume: 37, Issue:12 Topics: China; HIV Infections; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab	2023
Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma Turkish journal of haematology : official journal of Turkish Society of Haematology, 2023, 12-05, Volume: 40, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab; Treatment Outcome	2023
Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. British journal of haematology, 2019, Volume: 187, Issue:3 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Rituximab; Salvage Therapy; Skin Neoplasms	2019
Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. British journal of haematology, 2020, Volume: 188, Issue:4 Topics: Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Risk Factors; Survival Rate	2020
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Acta haematologica, 2020, Volume: 143, Issue:6 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Heart Neoplasms; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Pericardium	2020
Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab. International journal of hematology, 2020, Volume: 112, Issue:4 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Remission Induction; Rituximab; Treatment Outcome	2020
Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report. Medicine, 2020, Oct-23, Volume: 99, Issue:43 Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy	2020
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 04-10, Volume: 39, Issue:11 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Injections, Subcutaneous; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Prognosis; Rituximab; Transcription Factor CHOP	2021
Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 10-01, Volume: 27, Issue:19 Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse	2021
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. Blood advances, 2021, 08-10, Volume: 5, Issue:15 Topics: Central Nervous System; Humans; Incidence; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local	2021
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-15, Volume: 27, Issue:22 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Retrospective Studies	2021
Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 08-01, Volume: 35, Issue:22 Topics: Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine	2017
JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Scientific reports, 2017, 08-07, Volume: 7, Issue:1 Topics: Animals; Cell Adhesion Molecules; Cell Line, Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Neoplasm Invasiveness; Nodal Protein; Prognosis; Receptors, Cell Surface; Signal Transduction; Transforming Growth Factor beta; Up-Regulation; Xenograft Model Antitumor Assays; Zebrafish	2017
Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB. Experimental hematology, 2017, Volume: 56 Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Neoplasm Proteins; NIH 3T3 Cells; Peptide Hydrolases; Proteolysis; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases	2017
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 01-16, Volume: 115, Issue:3 Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Immunologic Factors; Interferon Type I; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Thalidomide	2018
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report. Medicine, 2018, Volume: 97, Issue:21 Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphadenopathy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Parotid Gland; Positron Emission Tomography Computed Tomography; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome	2018
Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment. Chinese medical journal, 2018, Oct-20, Volume: 131, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Salvage Therapy; Treatment Outcome	2018
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood cancer journal, 2018, 11-08, Volume: 8, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine	2018
Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. Journal of controlled release : official journal of the Controlled Release Society, 2019, 02-10, Volume: 295 Topics: Alginates; Antineoplastic Agents; Biomarkers, Tumor; Cell Culture Techniques; Cell Line; Cell Proliferation; Cell Survival; Cells, Cultured; Coculture Techniques; Drug Screening Assays, Antitumor; Equipment Design; Humans; Hydrogels; Immunologic Factors; Lab-On-A-Chip Devices; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Spheroids, Cellular; Tumor Cells, Cultured	2019
Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Prognosis; Treatment Outcome	2019
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. The oncologist, 2019, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Italy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Rituximab; Treatment Outcome	2019
Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide. Oral oncology, 2019, Volume: 93 Topics: Adult; Brain Edema; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Injections, Spinal; Intensive Care Units; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Nivolumab; Treatment Outcome	2019
Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. Annals of hematology, 2014, Volume: 93, Issue:2 Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms; Thalidomide	2014
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:11 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Rituximab; Thalidomide; Thrombocytopenia; Treatment Outcome	2014
Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide. Annals of hematology, 2014, Volume: 93, Issue:11 Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Radiography; Thalidomide; Treatment Outcome	2014
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. Journal of medical case reports, 2014, Oct-02, Volume: 8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Radiotherapy, Adjuvant; Recurrence; Rituximab; Salvage Therapy; Thalidomide	2014
Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type. Annals of hematology, 2015, Volume: 94, Issue:5 Topics: Aged; Female; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Thalidomide	2015
R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma. Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Thalidomide; Vincristine	2014
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer science, 2016, Volume: 107, Issue:5 Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation	2016
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. Journal of experimental & clinical cancer research : CR, 2016, Mar-24, Volume: 35 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinolines; Thalidomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2016
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. Hematological oncology, 2017, Volume: 35, Issue:4 Topics: Aged; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Survival Rate; Thalidomide	2017
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? The oncologist, 2016, Volume: 21, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Secondary Prevention; Thalidomide; Treatment Outcome	2016
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine	2016
50th ASH Annual Meeting. The Lancet. Oncology, 2009, Volume: 10, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Nadroparin; Rituximab; Thalidomide; Thromboembolism; Uric Acid	2009
Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leukemia & lymphoma, 2010, Volume: 51, Issue:9 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Salvage Therapy; Thalidomide	2010
Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). American journal of hematology, 2011, Volume: 86, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Dexamethasone; Female; Fluorodeoxyglucose F18; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Positron-Emission Tomography; Radiopharmaceuticals; Thalidomide	2011
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer, 2011, Nov-15, Volume: 117, Issue:22 Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Germinal Center; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prognosis; Recurrence; Thalidomide; Treatment Outcome	2011
Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20 Topics: Antineoplastic Agents; Eye Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Thalidomide	2011
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer cell, 2012, Jun-12, Volume: 21, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Interferon-beta; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Transcription Factors; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays	2012
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. British journal of haematology, 2013, Volume: 160, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Cell CLL-Lymphoma 10 Protein; CARD Signaling Adaptor Proteins; Caspases; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Guanylate Cyclase; Humans; Interferon Regulatory Factors; Interleukin-1 Receptor-Associated Kinases; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Mutation; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neoplasm Transplantation; NF-kappa B; Peptide Hydrolases; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases	2013
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007
Lenalidomide-associated hypothyroidism. Leukemia & lymphoma, 2007, Volume: 48, Issue:12 Topics: Antineoplastic Agents; Female; Humans; Hypothyroidism; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Thalidomide	2007